BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript Summary
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript Summary
Selling, General and Administrative expenses reduced to $825,000 in Q3 2024 from $1.1 million in Q3 2023.The following is a summary of the BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript:
以下是biocardia, Inc. (BCDA) 2024年第三季度業績會會議記錄的摘要：
Financial Performance:
財務表現：
BioCardia reported a decrease in total expenses by 41% from Q3 2023 to Q3 2024, with $1.8 million in Q3 2024 compared to $3.0 million in Q3 2023.
Research and Development expenses decreased to $931,000 in Q3 2024, down from $1.9 million in Q3 2023, attributed to the completion of enrollment in the CardiAMP Heart Failure I trial.
Selling, General and Administrative expenses reduced to $825,000 in Q3 2024 from $1.1 million in Q3 2023.
Net loss decreased to $1.7 million in Q3 2024 from $2.6 million in the third quarter of 2023.
Net cash used in operations totaled $2.6 million in Q3 2024, as compared to $2.4 million in Q3 2023.
biocardia在2024年第三季度的總支出相比於2023年第三季度減少了41%，在2024年第三季度的支出爲180萬，而2023年第三季度爲300萬。
研發支出在2024年第三季度減少至931,000美元，低於2023年第三季度的190萬，主要歸因於心臟再生治療I期試驗的入組完成。
銷售、一般和行政支出從2023年第三季度的110萬降至2024年第三季度的825,000。
淨虧損從2023年第三季度的260萬減少至2024年第三季度的170萬。
2024年第三季度的運營淨現金使用總額爲260萬，而2023年第三季度爲240萬。
Business Progress:
業務進展：
BioCardia is advancing two major clinical trials for CardiAMP cell therapy, looking toward cardiac repair without the need for surgery or immunosuppression.
Lead CardiAMP cell therapy for heart failure has received FDA breakthrough designation and is reimbursed by CMS.
Enrollment boost in CardiAMP Heart Failure II trial is expected due to protocol amendments and additional cell dosage adjustments.
The Morph DNA Steerable Introducer received FDA approval, enhancing cardiac procedures.
biocardia正在推進兩項主要的心臟AMP電芯療法臨床試驗，旨在實現無需手術或免疫抑制的心臟修復。
用於心衰的心臟AMP電芯療法已獲得FDA突破性設計，並得到康哲藥業的報銷。
由於協議修訂和額外電芯劑量調整，預計心臟AMP心衰II試驗的 enrollment 會增加。
Morph DNA可控引導器已獲得FDA批准，提升了心臟程序的安全性。
Opportunities:
機會：
Expansion in the CardiAMP Heart Failure II trial with protocol amendment, allowing for increased eligibility and potential effectiveness.
Marketing the Morph DNA Steerable Introducer to other companies could provide substantial non-dilutive capital and expedite commercial expansion.
心臟AMP心衰II試驗的擴展通過協議修訂，允許更高的適應資格和潛在的有效性。
向其他公司銷售Morph DNA可控引導器可以提供大量非稀釋性資本，並加快商業擴展。
Risks:
風險：
Final data from the CardiAMP Heart Failure I trial pivotal for future product approvals might bear unexpected outcomes.
Delays in clinical trials due to natural disasters like hurricanes impacting timelines and operations.
來自CardiAMP心力衰竭I期試驗的最終數據可能對未來產品審批產生意想不到的結果。
由於像颶風這樣的自然災害導致的臨床試驗延遲影響時間表和操作。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
